国际中医中药杂志
國際中醫中藥雜誌
국제중의중약잡지
INTERNATIONAL JOURNAL OF TRIDITIONAL CHINESE MEDICINE
2008年
6期
445-446
,共2页
肺原性心脏病%心力衰竭%参附注射液%黄芪注射液%川芎嗪注射液
肺原性心髒病%心力衰竭%參附註射液%黃芪註射液%川芎嗪註射液
폐원성심장병%심력쇠갈%삼부주사액%황기주사액%천궁진주사액
Heart failure%Chronic pulmonary heart disease%"Shen fu"injection%Astragalus iMecfion%Tetramethylpyrazine injecfion
目的 观察参附注射液、黄芪注射液与川芎嗪注射液配合西医常规疗法治疗慢性肺原性心脏病心力衰竭的临床疗效.方法 将60例慢性肺原性心脏病心力衰竭患者随机分为治疗组32例和对照组28例,对照组采用西医常规治疗,治疗组在西医常规治疗的基础上加用参附注射液、黄芪注射液和川芎嗪注射液治疗,比较两组疗效.结果 治疗组总有效率93.75%、对照组53.57%,两组疗效有显著性差异(P＜0.01):病死率治疗组为0、对照组为17.86%,两组比较有显著性差异(P＜0.05).结论 参附注射液、黄芪注射液和川芎嗪注射液治疗慢性肺原性心脏病心力衰竭可降低肺动脉压、改善心功能、降低病死率,疗效显著.
目的 觀察參附註射液、黃芪註射液與川芎嗪註射液配閤西醫常規療法治療慢性肺原性心髒病心力衰竭的臨床療效.方法 將60例慢性肺原性心髒病心力衰竭患者隨機分為治療組32例和對照組28例,對照組採用西醫常規治療,治療組在西醫常規治療的基礎上加用參附註射液、黃芪註射液和川芎嗪註射液治療,比較兩組療效.結果 治療組總有效率93.75%、對照組53.57%,兩組療效有顯著性差異(P＜0.01):病死率治療組為0、對照組為17.86%,兩組比較有顯著性差異(P＜0.05).結論 參附註射液、黃芪註射液和川芎嗪註射液治療慢性肺原性心髒病心力衰竭可降低肺動脈壓、改善心功能、降低病死率,療效顯著.
목적 관찰삼부주사액、황기주사액여천궁진주사액배합서의상규요법치료만성폐원성심장병심력쇠갈적림상료효.방법 장60례만성폐원성심장병심력쇠갈환자수궤분위치료조32례화대조조28례,대조조채용서의상규치료,치료조재서의상규치료적기출상가용삼부주사액、황기주사액화천궁진주사액치료,비교량조료효.결과 치료조총유효솔93.75%、대조조53.57%,량조료효유현저성차이(P＜0.01):병사솔치료조위0、대조조위17.86%,량조비교유현저성차이(P＜0.05).결론 삼부주사액、황기주사액화천궁진주사액치료만성폐원성심장병심력쇠갈가강저폐동맥압、개선심공능、강저병사솔,료효현저.
Objective To observe the therapeutic efficacy of combined use of"shen fu"injection(参附注射液),astragalus injecfion and tetramethylpyrazine injection in the treatment of heart failure due to chronic pulmonary heart disease.Methods 60 cases were randomly divided into a control guoup(n=28),which was treated with routine therapy and a treatment group(n=32),which was treated with"shen fu"injection,astmgalus injecdon and tetramethylpyrazine injection on basis of routinc therapy.Results The total effective rates were 93.8%and 53.6%in the treatment group and the control group respectively,demonstrating a obvious difference between the 2 groups(P＜0.01).The mortality is zero in the treatment group comparing with 17.9%in the control group.showing obvious difference between the 2 groups(P＜0.05).Conclusion Combined use of"shen fu"injection,astragalus injection and tetramethylpyrazine injection can decrease pulmonary artery pressure,improve cardiac performance and decrease mortality in the treatment of heart failure due to chronic pulmonary heart disease.
